C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease

Stroke

Volumn 37, Issue 7, 2006, Pages 1720-1724

  Tanne, David ^a,d   Benderly, Michal ^a,d   Goldbourt, Uri ^a,d   Haim, Moti ^b,d   Tenenbaum, Alexander ^a,d   Fisman, Enrique Z ^a,d   Matas, Zipora ^c,d   Adler, Yehuda ^a,d   Zimmlichman, Reuven ^c,d   Behar, Solomon ^a,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Epidemiology; Inflammation; Risk factors; Stroke

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; PLACEBO; ANTILIPEMIC AGENT; FIBRINOGEN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; SAMPLE; TIME SERIES ANALYSIS; ANGINA PECTORIS; BLOOD; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEART INFARCTION; HYPERCHOLESTEROLEMIA; INCIDENCE; ISRAEL; LIFE TABLE; MIDDLE AGED; MULTICENTER STUDY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT;

AGED; ANGINA PECTORIS; ANTILIPEMIC AGENTS; BEZAFIBRATE; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBRAL INFARCTION; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; INCIDENCE; ISRAEL; LIFE TABLES; MALE; MIDDLE AGED; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK; RISK ASSESSMENT;

EID: 33745947105     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000227004.08182.bf     Document Type: Article

References (29)

1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
2. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004;35:2300-2305.
3. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36:1316-1329.
4. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799-1809.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:843-846.
6. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
7. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
8. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study. Stroke. 2001;32:2575-2579.
9. Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, Tracy RP. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107:2016-2020.
10. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study. Circulation. 2003;108:2317-2322.
11. Wakugawa Y, Kiyohara Y, Tanizaki Y, Kubo M, Ninomiya T, Hata J, Doi Y, Okubo K, Oishi Y, Shikata K, Yonemoto K, Maebuchi D, Ibayashi S, Iida M. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke. 2005;37:27-32.
12. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PHM, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108:166-170.
13. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466.
14. The Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21-27.
15. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) study. Eur Heart J. 1998;19(suppl H):H42-H47.
16. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, Graff E, Reicher-Reiss H, Shotan A, Mandelzweig L, Behar S. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the Bezafibrate Infarction Prevention study. Am J Med. 2001;111:457-463.
17. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation. 2004;109:1955-1959.
18. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005;4:371-380.
19. Woodward M, Lowe GDO, Campbell DJ, Colman S, Rumley A, Chalmers J, Neal BC, Patel A, Jenkins AJ, Kemp BE, MacMahon SW. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke. 2005;36:2143-2147.
20. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2002;144:233-238.
21. van Exel E, Gussekloo J, de Craen AJM, Bootsma-van der Wiel A, Frolich M, Westendorp RGJ. Inflammation and stroke: the Leiden 85-Plus study. Stroke. 2002;33:1135-1138.
22. Tanne D, Haim M, Boyko V, Goldbourt U, Reshef T, Matetzky S, Adler Y, Mekori YA, Behar S. Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort. Stroke. 2002;33:2182-2186.
23. Oei H-HS, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, Witteman JCM. Lipoprotein-associated phospholipase a2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation. 2005;111:570-575.
24. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:2094-2099.
25. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan study. Circulation. 2005;112:900-905.
26. Schillinger M, Exner M, Mlekusch W, Sabeti S, Amighi J, Nikowitsch R, Timmel E, Kickinger B, Minar C, Pones M, Lalouschek W, Rumpold H, Maurer G, Wagner O, Minar E. Inflammation and Carotid Artery-Risk for Atherosclerosis Study (ICARAS). Circulation. 2005;111:2203-2209.
27. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154-1160.
28. Nicklas BJ, You T, Pahor M. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. CMAJ. 2005;172:1199-1209.
29. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: the Attica study. J Am Coll Cardiol. 2004;44:152-158.